Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9842231 | 0.71 | — | — | |
| SCHEMBL987964 | 0.70 | DNM1 (0.32) | DNM1 | |
| SCHEMBL9842135 | 0.69 | — | — | |
| SCHEMBL4600945 | 0.66 | — | — | |
| SCHEMBL4131700 | 0.66 | ALDH1A1 (0.37) | DNM1 | |
| SCHEMBL79197 | 0.64 | ALDH1A1 (0.46) | DNM1 | |
| SCHEMBL159549 | 0.64 | DNM1 (0.39) | DNM1 | |
| SCHEMBL11455587 | 0.64 | LMNA (0.42) | DNM1 | |
| SCHEMBL4362883 | 0.64 | DNM1 (0.46) | DNM1 | |
| SCHEMBL1995923 | 0.64 | DNM1 (0.35) | DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582627-B2 | 3-Amino-7-[3-(1-aminoethyl)-4-fluoropyrrolidin-1-yl]-1-cyclopropyl-8-methyl-1H-pyrido[4,3-d]pyrimidine-2,4-dione; quinolone antibiotics; bactericides; for antibiotic- resistant bacterial infections, ciprofloxacin- resistant ones; inhibiting wild-type and quinolone- resistant mutants of DNA gryase | WARNER-LAMBERT COMPANY (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1255739-B1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ZOETIS WLC LLC | 2006-12-21 | — | — | US | disclosed |
| US-7094780-B1 | 3-aminoquinazolin-2,4-dione antibacterial agents | WARNER LAMBERT COMPANY LLC (US) | 2006-08-22 | — | — | US | disclosed |
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ZOETIS WLC LLC | 2006-08-17 | — | — | US | disclosed |
| EP-1395585-B1 | ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2006-01-04 | — | — | EP | disclosed |
| EP-1577305-A1 | Oral antidiabetic agents | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-21 | — | — | EP | disclosed |
| US-6924377-B2 | Process for preparing highly functionalized γ-butyrolactams and γ-amino acids | WARNER-LAMBERT COMPANY (US) | 2005-08-02 | — | — | US | disclosed |
| US-6864259-B2 | Antibacterial agents | WARNER-LAMBERT COMPANY (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1499583-A1 | PROCESS FOR PREPARING HIGHLY FUNCTIONALIZED Y-BUTYROLACTAMS AND Y-AMINO ACIDS | Warner-Lambert Company LLC (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003084535-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003082276-A1 | ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030171377-A1 | Antidiabetic agents | BIGGE CHRISTOPHER FRANKLIN (US) | 2003-09-11 | — | — | US | disclosed |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
| US-20030114458-A1 | Antibacterial agents | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
| WO-2003018553-A1 | ORAL ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-06 | — | — | WO | disclosed |
| WO-2002102793-A2 | QUINAZOLINEDIONES AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-27 | — | — | WO | disclosed |
| WO-2002096908-A1 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2002-12-05 | — | — | WO | disclosed |
| EP-1255739-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001053273-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171377-A1 | Antidiabetic agents | SLC5A1, SLC5A2, GLP1R | DNM1 1809/4885 |
| US-20060183762-A1 | 3-AMINOQUINAZOLIN-2,4-DIONE ANTIBACTERIAL AGENTS | ABL1, NQO2, CBR3 | DNM1 957/4885 |
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | DNM1 1119/4885 |
| US-20030114458-A1 | Antibacterial agents | MRPL21, RPS6, RPS6KA1 | DNM1 429/4885 |
| US-20060287308-A1 | 3-Aminoquinazolin-2,4-dione antibacterial agents | ABL1, NQO2, AAAS | DNM1 894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.